SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a 1.4 billion dollar convertible debt exchange for equity, a move that aims to reduce long-term debt while fueling community debate over shareholder dilution and corporate strategy. Investors remain sharply divided, with some betting on a potential acquisition as a long-term catalyst while others voice frustration over the stock's stagnation and the impact of frequent share issuance.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is currently the focus of intense investor attention as an FDA advisory committee evaluates the efficacy of its lead cancer therapy, RP1, following past regulatory setbacks. Community discussion is sharply divided between those betting on a successful approval as a major catalyst for a short squeeze and skeptics pointing to FDA briefing documents, potential dilution, and the history of prior rejections.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors react to a mix of strong Q2 growth, including double-digit revenue gains and record monthly transacting users, while debating the impact of store-level margin compression and same-store sales trends. Community sentiment remains polarized, with long-term supporters highlighting the company's aggressive store expansion and successful share repurchases as catalysts for future upside, while skeptics point to the risks inherent in OTC-listed Chinese ADRs and ongoing competition in the beverage space.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is experiencing a surge in investor attention and high-stakes options activity ahead of its upcoming earnings report, with the community closely tracking the company's progress in scaling autonomous delivery operations and physical AI. Traders are actively debating the potential for a short squeeze, fueled by significant short interest and speculation regarding future enterprise partnerships or a potential buyout, as bullish sentiment grows around the firm's expansion into new markets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as the community reacts to a price target hike and the launch of a new clinical trial for its drug in treatment-resistant schizophrenia, fueling speculation about potential acquisition value. Despite conflicting analyst ratings and persistent short interest, bullish investors are focused on the company's strong commercial execution, its path to significant annual revenue, and the strategic optionality provided by its expanding autoimmune pipeline.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly await Phase 3 IZAR-1 clinical trial results, with community speculation heavily focused on whether the data release will coincide with upcoming quarterly earnings. The stock is currently subject to intense discussion regarding its potential as a 'best-in-class' treatment for psoriatic arthritis, with many market participants viewing the current price consolidation as a strategic entry point before a anticipated major catalyst.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is seeing intense investor focus following a string of major capacity-reservation agreements with industry giants, fueling a debate over whether these deals signal a fundamental inflection point for its semiconductor substrates or if the stock's valuation has detached from its near-term financials. Community discussion remains polarized, with some traders betting on a significant short squeeze and long-term photonics demand, while others caution against high-beta volatility and ongoing export permit risks.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is experiencing a volatile market reaction as investors weigh strong earnings and solid revenue performance against softer-than-expected full-year guidance. The community remains deeply divided, with some traders focusing on short-term price action and potential overvaluation concerns, while long-term bulls point to a robust backlog and the company's competitive advantage in domestic manufacturing as catalysts for future stability.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending as investors react to a flurry of R&D-focused deal activity, including a new licensing agreement with Janux Therapeutics and collaborative efforts with Microsoft to advance AI in oncology. The community is actively debating the company's long-term growth prospects as management attempts to address upcoming patent cliffs through a mix of strategic acquisitions, cost-cutting initiatives, and a renewed emphasis on its newer clinical-stage pipeline.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is currently at the center of market attention due to reports of potential merger talks with Bristol Myers Squibb in a deal that could be valued at approximately $400 billion. Investors are actively debating the potential for portfolio synergies in oncology, while the market remains sensitive to the inherent risks and antitrust complications associated with a transaction of this magnitude.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -87.81% and +4.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run

Key PointsThe executive disposed of 3,313 shares on July 2, 2026, for a total transaction value of about $285,000...

ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge

Key PointsAn ANI Pharmaceuticals executive reported selling 2,850 shares directly for about $240,000 on June 29, 2026...

Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?

ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.

ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push

ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.

ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth

ANIP bets on Cortrophin Gel to power 2026 growth as rare disease sales become the majority of revenues. What must keep working?

$ANIP Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $1.31 up 87.14% YoY
• Reported revenue of $237.46M up 20.46% YoY
• ANI Pharmaceuticals expects to receive $10M upon achievement of certain development milestones, which are anticipated in the second and third quarters of 2026.

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI Pharmaceuticals Inc

ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$2.04	--	--	N/A
Q1 '26	$1.30	$2.05	57.84%	BEAT
Q4 '25	$1.98	$2.33	17.55%	BEAT
Q3 '25	$1.77	$2.04	15.25%	BEAT
Q2 '25	$1.41	$1.80	28.05%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings